Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection.

Literature DB >> 3306422

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection.

J J Fung, A J Demetris, K A Porter, S Iwatsuki, R D Gordon, C O Esquivel, R Jaffe, A Tzakis, B W Shaw, T E Starzl.

Abstract

OKT3 monoclonal antibody therapy was added to preexisting baseline immunosuppressive treatment with ciclosporin and steroids to treat rejection in 52 recipients of cadaveric livers and 10 recipients of cadaveric kidneys. Rejection was controlled in 75% of patients treated, often after high-dose steroid therapy had failed. Rejection recurred during the 17-month follow-up period, after completion of OKT3, in only 25% of the patients who had responded. The safety and effectiveness of this monoclonal therapy, added to ciclosporin and steroids, has been established in this study.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1987 PMID： 3306422 PMCID： PMC2994552 DOI： 10.1159/000184431

Source DB: PubMed Journal: Nephron ISSN： 1660-8151 Impact factor: 2.847

38 in total

1. THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE.

Authors: T E STARZL; T L MARCHIORO; W R WADDELL
Journal: Surg Gynecol Obstet Date: 1963-10

2. RENAL FAILURE IN PATIENTS WITH CIRRHOSIS OF THE LIVER. I. CLINICAL AND PATHOLOGIC CHARACTERISTICS.

Authors: L SHEAR; J KLEINERMAN; G J GABUZDA
Journal: Am J Med Date: 1965-08 Impact factor: 4.965

3. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation.

Authors: T E Starzl; T L Marchioro; K A Porter; Y Iwasaki; G J Cerilli
Journal: Surg Gynecol Obstet Date: 1967-02

4. Survival of skin heterografts under treatment with antilymphocytic serum.

Authors: E M Lance; P B Medawar
Journal: Lancet Date: 1968-06-01 Impact factor: 79.321

Review 5. Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation.

Authors: R Venkataramanan; G J Burckhart; R J Ptachcinski
Journal: Semin Liver Dis Date: 1985-11 Impact factor: 6.115

6. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.

Authors: A B Cosimi; R C Burton; R B Colvin; G Goldstein; F L Delmonico; M P LaQuaglia; N Tolkoff-Rubin; R H Rubin; J T Herrin; P S Russell
Journal: Transplantation Date: 1981-12 Impact factor: 4.939

7. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.

Authors:
Journal: N Engl J Med Date: 1985-08-08 Impact factor: 91.245

8. A reappraisal of the effects of monoclonal antibodies directed at T cell differentiation antigens.

Authors: M Suthanthiran; M Evelyn; A L Rubin; K H Stenzel
Journal: Transplantation Date: 1984-12 Impact factor: 4.939

9. Renal failure in children with hepatic failure undergoing liver transplantation.

Authors: D Ellis; E D Avner; T E Starzl
Journal: J Pediatr Date: 1986-03 Impact factor: 4.406

10. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection.

Authors: J R Thistlethwaite; A B Cosimi; F L Delmonico; R H Rubin; N Talkoff-Rubin; P W Nelson; L Fang; P S Russell
Journal: Transplantation Date: 1984-12 Impact factor: 4.939

32 in total

1. The point system for organ distribution.

Authors: T E Starzl; R Shapiro; L Teperman
Journal: Transplant Proc Date: 1989-06 Impact factor: 1.066

2. Transplantation.

Authors: Thomas E Starzl
Journal: JAMA Date: 1986-10-17 Impact factor: 56.272

3. WHICH LIVER-DESEASE PATIENTS NEED A TRANSPLANT?: Organ replacement has come into its own as a treatment for end-stage liver disease. A team of experts from two leading transplant centers reviews current indications, survival rates, and methods of evaluating candidates for operation.

Authors: Leonard Makowka; Linda Sher; Delawir Kahn; Thomas E Starzl; A G Tzakis; S Todo; J W Marsh; A Stieber; B Koneru; G B G Klintmalm; S M Staschak; S Iwatsuki; R D Gordon; D Van Thiel
Journal: Hosp Rec Study Date: 1988-06

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection.

1. THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE.

2. RENAL FAILURE IN PATIENTS WITH CIRRHOSIS OF THE LIVER. I. CLINICAL AND PATHOLOGIC CHARACTERISTICS.

3. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation.

4. Survival of skin heterografts under treatment with antilymphocytic serum.

Review 5. Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation.

6. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.

7. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.

8. A reappraisal of the effects of monoclonal antibodies directed at T cell differentiation antigens.

9. Renal failure in children with hepatic failure undergoing liver transplantation.

10. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection.

1. The point system for organ distribution.

2. Transplantation.

3. WHICH LIVER-DESEASE PATIENTS NEED A TRANSPLANT?: Organ replacement has come into its own as a treatment for end-stage liver disease. A team of experts from two leading transplant centers reviews current indications, survival rates, and methods of evaluating candidates for operation.

4. Orthotopic liver transplantation for alcoholic cirrhosis.

Review 5. Current status of renal transplantation.

6. Origin of lymph node-derived lymphocytes in human hepatic allografts.

7. The antibody crossmatch in liver transplantation.

8. Red cell antibody problems in 1000 liver transplants.

9. Donor gender does not affect liver transplantation outcome in children.

10. Pediatric liver transplantation.